New data draws upon ongoing research to highlight MammaPrint® + BluePrint® utility in early-stage breast cancer treatment planning.

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 24, 2024 – Agendia®, Inc., announced today that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 31st – June 4th, 2024, in Chicago, Illinois.

The presented data underscores Agendia’s commitment to advancing individualized management of breast cancer and to providing support throughout a patient’s treatment journey. These studies add to the already robust library of clinical studies demonstrating Agendia’s MammaPrint and BluePrint effectiveness in providing reliable guidance for therapeutic considerations in early-stage breast cancer.

The two abstracts that have been selected by ASCO for oral discussion will 1) feature an investigation of underlying biology that mediates immune therapy response and, 2) will provide an evaluation of the MammaPrint Index and 3-year recurrence-free interval in patients treated with CT, with and without anthracycline. Both presentations utilize whole transcriptome data from the prospective, observational real-word evidence FLEX Study (NCT03053193).

The following are details of the abstracts that have been accepted at the ASCO 2024 Annual Meeting:

Oral Discussion

Authors: O’Shaughnessy, J., et al.

Presenter: Joyce O’Shaughnessy, MD | Baylor-Sammons Cancer Center, Texas Oncology

Session: Rapid Oral Abstract – Breast Cancer – Local/Regional/Adjuvant

Poster Discussion: Friday, May 31, 2024 | 2:45 PM – 4:15 PM CDT

Abstract #: 511


Authors: Cobain, E., et al.

Presenter: Erin Cobain, MD | University of Michigan Rogel Cancer Center

Session: Oral Abstract Session – Breast Cancer – Local/Regional/Adjuvant

Poster Discussion: Monday, June 3, 2024 | 3:00 PM – 6:00 PM CDT

Abstract #: 506

Poster sessions

Authors: Lux M.P., Sandor M. F., Hofmann V., Pronin D., Klinkhamer J.C., Müller-Huesmann H.

Presenter: Harald Müller-Huesmann | St. Josef Brothers Hospital Paderborn, Germany

Session Date & Time: Sunday, June 2, 2024 | 9:00 AM – 12:00 PM CDT

Abstract #: 534

Other Investigator Initiated Abstracts Utilizing MammaPrint + BluePrint:

Authors: Alejandro Rios-Hoyo; Lajos Pusztai

Session Date & Time: Sunday, 2, 2024 | 9:00AM-12:00PM CDT

Abstract #: 573

Authors: Valdez, et al.

Abstract #: e12541

More information about the program can be found at the ASCO 2024 website.

Media Contact

Terri Clevenger

ICR Westwicke Healthcare PR

Tel: 203.682.8297